GlassScriptPhysician profile
Michael G Ludlow
NPI 1124136239
$1,681.70
in general payments reported to CMS, 2019-2025
27 companies · $59.82 in 2025
The $59.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $186 · 2021: $303 · 2022: $342 · 2023: $110 · 2024: $67.52 · 2025: $59.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $279.79 | 2019-2025 | |
| Lilly USA, LLC | $243.83 | 2019-2023 | Mounjaro |
| Amgen INC. | $240.96 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.06 | 2019-2022 | |
| Esperion Therapeutics, INC. | $125.80 | 2021 | |
| Abbvie INC. | $104.13 | 2019-2022 | |
| Nevro Corp. | $68.04 | 2022-2023 | Senza |
| Novo Nordisk INC | $52.70 | 2020-2022 | |
| Medtronic, INC. | $52.09 | 2022-2025 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $48.10 | 2021 | |
| Abbott Laboratories | $32.77 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $25.00 | 2020-2023 | Farxiga |
| Eisai INC. | $24.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.06 | 2022 | |
| Cranial Technologies, INC | $20.61 | 2024 | Doc Band |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.59 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.33 | 2022 | |
| Sanofi Pasteur INC. | $17.89 | 2019 | |
| Pacira Therapeutics, INC. | $16.33 | 2020 | |
| Shire North American Group INC | $14.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.50 | 2022 | |
| Electromed, INC. | $14.43 | 2021 | |
| Astellas Pharma US INC | $14.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.83 | 2021 | |
| Daiichi Sankyo INC. | $12.52 | 2021 | |
| Amarin Pharma, INC. | $11.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ludlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.